DNMR - Danimer Scientific Stock Price, Fair Value and News

0.78USD0.00 (0.00%)Delayed as of 16 Apr 2024, 02:54 pm ET

Market Summary

USD0.780.00

Delayedas of 16 Apr 2024, 02:54 pm

0.00%

DNMR Stock Price

View Fullscreen

DNMR RSI Chart

DNMR Valuation

Market Cap

89.1M

Price/Earnings (Trailing)

-0.57

Price/Sales (Trailing)

1.91

EV/EBITDA

-0.11

Price/Free Cashflow

-1.19

DNMR Price/Sales (Trailing)

DNMR Profitability

Operating Margin

-57.75%

EBT Margin

-332.35%

Return on Equity

-55.92%

Return on Assets

-22.27%

Free Cashflow Yield

-84.11%

DNMR Fundamentals

DNMR Revenue

Revenue (TTM)

46.7M

Rev. Growth (Yr)

-28.58%

Rev. Growth (Qtr)

-0.03%

DNMR Earnings

Earnings (TTM)

-155.5M

Earnings Growth (Yr)

-40.58%

Earnings Growth (Qtr)

1.81%

Breaking Down DNMR Revenue

52 Week Range

0.754.28

(Low)(High)

Last 7 days

-25.7%

Last 30 days

-42.2%

Last 90 days

1.3%

Trailing 12 Months

-80.9%

How does DNMR drawdown profile look like?

DNMR Financial Health

Current Ratio

6.87

DNMR Investor Care

Shares Dilution (1Y)

12.07%

Diluted EPS (TTM)

-2.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	50.4M	50.6M	51.1M	46.7M
2022	60.3M	58.5M	55.6M	53.2M
2021	49.9M	52.5M	53.0M	58.7M
2020	36.1M	39.8M	43.6M	47.3M
2019	0	0	0	32.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Danimer Scientific

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	hajost michael a	acquired	-	-	34,364	chief financial officer
Feb 07, 2024	hajost michael a	sold (taxes)	-7,970	0.66	-12,076	chief financial officer
Dec 29, 2023	van trump phillip d	sold (taxes)	-19,304	1.02	-18,926	chief technology officer
Dec 29, 2023	tuten scott	sold (taxes)	-19,304	1.02	-18,926	chief marketing officer
Dec 29, 2023	smith michael eric	sold (taxes)	-28,925	1.02	-28,358	chief operating officer
Nov 28, 2023	hendrix richard j	bought	46,480	0.9296	50,000	-
Nov 28, 2023	hendrix richard j	bought	46,915	0.9383	50,000	-
Jun 20, 2023	tuten scott	sold	-27,390	2.739	-10,000	chief marketing officer
May 17, 2023	tuten scott	sold	-33,810	3.381	-10,000	chief marketing officer
Apr 17, 2023	tuten scott	sold	-42,619	4.2619	-10,000	chief marketing officer

Which funds bought or sold DNMR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Allen Mooney & Barnes Investment Advisors LLC	unchanged	-	-15,709	86,154	0.02%
Apr 12, 2024	Game Plan Financial Advisors, LLC	sold off	-100	-41.00	-	-%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	sold off	-100	-408	-	-%
Apr 12, 2024	waypoint wealth counsel	unchanged	-	737	11,477	0.01%
Apr 10, 2024	Thomasville National Bank	added	125	113,509	193,851	0.02%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	10.00	153	-%
Apr 08, 2024	Atlas Brown,Inc.	unchanged	-	2,079	32,373	0.01%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	-	2,000	-%
Apr 05, 2024	CWM, LLC	reduced	-26.14	-	2,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-13.49	-28,497	21,176	-%

Are Funds Buying or Selling DNMR?

Are funds buying DNMR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNMR

No. of Funds

Unveiling Danimer Scientific's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2024	blackrock inc.	6.1%	6,248,580	SC 13G/A
Feb 09, 2023	vanguard group inc	4.86%	4,924,554	SC 13G/A
Feb 08, 2023	invesco ltd.	2.6%	2,664,502	SC 13G/A
Feb 01, 2023	blackrock inc.	5.9%	5,969,531	SC 13G/A
Feb 14, 2022	invesco ltd.	6.4%	6,376,582	SC 13G
Feb 09, 2022	vanguard group inc	8.00%	8,028,738	SC 13G
Feb 04, 2022	blackrock inc.	5.5%	5,550,559	SC 13G
Mar 22, 2021	croskrey stephen	5.8%	5,098,914	SC 13D
Feb 10, 2021	integrated core strategies (us) llc	0.0%	10,500	SC 13G/A
Jan 26, 2021	atalaya capital management lp	2.8%	2,381,076	SC 13G/A

Recent SEC filings of Danimer Scientific

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 01, 2024	424B3	Prospectus Filed
Mar 29, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 22, 2024	424B5	Prospectus Filed
Mar 21, 2024	424B5	Prospectus Filed

Peers (Alternatives to Danimer Scientific)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
APD	51.5B	12.4B	-5.47%	-19.20%	22.01	4.14	-3.54%	3.06%
DOW	40.4B	44.6B	0.47%	1.43%	61.28	0.91	-21.58%	-85.78%
CE	17.0B	10.9B	-2.67%	40.70%	8.66	1.55	13.10%	3.48%
AVTR	16.8B	7.0B	-1.48%	19.43%	52.2	2.41	-7.26%	-53.23%
ALB	14.1B	9.6B	-1.36%	-40.94%	8.99	1.47	31.38%	-41.50%
EMN	11.4B	9.2B	5.47%	17.54%	12.78	1.24	-12.95%	12.74%
MID-CAP
CBT	5.2B	3.9B	5.69%	23.87%	11.6	1.31	-9.12%	26.64%
BCPC	4.7B	922.4M	-6.20%	15.51%	43.61	5.13	-2.11%	3.01%
AVNT	3.8B	3.1B	2.37%	3.94%	50.24	1.22	-7.48%	-89.19%
ARCH	2.9B	3.1B	-1.93%	21.31%	6.28	0.92	-15.54%	-65.21%
SMALL-CAP
CCF	1.2B	404.0M	0.11%	32.60%	36.59	3	24.06%	-25.72%
ASIX	722.2M	1.5B	3.01%	-32.07%	13.22	0.47	-21.18%	-60.55%
CMT	178.7M	357.7M	7.50%	2.01%	8.79	0.5	-5.20%	66.55%
AREC	108.8M	16.7M	-15.24%	9.45%	9.82	6.5	-57.58%	866.09%
AMRS	3.7M	-	-80.00%	-99.58%	-0.01	0.01	-	-

Danimer Scientific News

Latest updates

Danimer Scientific Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	0.0%	10,945,000	10,948,000	12,865,000	11,926,000	15,324,000	10,448,000	12,703,000	14,743,000	17,728,000	13,369,000	14,471,000	13,181,000	12,027,000	12,835,000	11,873,000	10,598,000	-
Cost Of Revenue	-7.3%	17,317,000	18,685,000	19,433,000	18,209,000	18,078,000	14,503,000	14,934,000	16,065,000	20,079,000	13,601,000	12,460,000	11,725,000	10,818,000	9,188,000	8,441,000	7,429,000	-
Costs and Expenses	-0.5%	41,977,000	42,187,000	43,986,000	44,153,000	45,043,000	105,354,000	44,823,000	45,432,000	53,007,000	45,203,000	35,547,000	24,464,000	23,269,000	14,748,000	13,388,000	11,656,000	-
S&GA Expenses	2.0%	16,885,000	16,555,000	16,844,000	18,699,000	19,256,000	19,413,000	20,975,000	22,236,000	24,213,000	26,592,000	19,079,000	10,120,000	10,165,000	3,370,000	2,828,000	2,980,000	-
R&D Expenses	10.1%	7,575,000	6,883,000	7,709,000	7,075,000	7,709,000	7,947,000	8,913,000	7,131,000	8,666,000	5,010,000	3,975,000	2,619,000	2,286,000	2,190,000	2,128,000	1,247,000	-
EBITDA Margin	-18.5%	-3.14	-2.65	-3.66	-3.39	-3.04	-2.75	-1.06	0.11	-1.06	-1.06	-1.08	-1.98	-	-	-	-	-
Interest Expenses	100.0%	-	-8,584,000	-9,162,000	-3,386,000	474,000	-553,000	-652,000	-992,000	-1,278,500	164,000	203,000	148,000	-3,511,000	334,000	384,000	713,000	-
Income Taxes	-97.2%	14,000	500,000	-100,000	-90,000	-26,500	-236,000	-240,000	-291,000	-1,810,000	-11,423,000	-	-	-	-	-	-	-
Earnings Before Taxes	0.7%	-39,432,000	-39,691,000	-39,302,000	-36,729,000	-28,094,000	-95,112,000	-30,685,000	-26,677,000	-14,256,000	-3,598,000	39,248,000	-94,734,000	-3,233,000	-2,139,000	-1,800,000	-1,681,000	-
EBT Margin	-18.0%	-3.32	-2.82	-3.94	-3.78	-3.39	-3.00	-1.28	-0.09	-1.25	-1.17	-1.16	-2.04	-	-	-	-	-
Net Income	1.8%	-39,434,000	-40,159,000	-39,241,000	-36,639,000	-28,051,000	-94,876,000	-30,445,000	-26,386,000	-12,446,000	7,825,000	39,248,000	-94,734,000	-3,233,000	-2,139,000	-1,800,000	-1,681,000	-
Net Income Margin	-18.0%	-3.33	-2.82	-3.93	-3.77	-3.38	-2.95	-1.05	0.14	-1.02	-0.96	-1.16	-2.04	-	-	-	-	-
Free Cashflow	-39.1%	-17,896,000	-12,861,000	-21,927,000	-22,265,000	-35,109,000	-44,971,000	-69,736,000	-76,507,000	-104,135,000	-69,692,000	-36,446,000	-38,101,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-3.2%	698	721	744	779	712	733	791	812	839	650	646	512	546	202	202	145
Current Assets	-15.0%	108	127	145	178	125	163	202	267	340	239	452	346	402	2.00	2.00	19.00
Cash Equivalents	-5.0%	74.00	77.00	91.00	102	63.00	101	141	211	287	196	417	10.00	380	6.00	8.00	6.00
Inventory	-5.3%	25.00	27.00	30.00	32.00	33.00	35.00	33.00	28.00	25.00	24.00	18.00	17.00	14.00	-	-	7.00
Net PPE	-1.0%	445	450	454	455	454	437	409	365	316	223	160	130	107	-	-	72.00
Goodwill	-	-	-	-	-	-	-	63.00	63.00	63.00	67.00	-	-	-	-	-	-
Liabilities	0.8%	420	417	414	423	335	342	319	325	338	121	139	230	190	169	149	128
Current Liabilities	6.5%	16.00	15.00	15.00	25.00	25.00	32.00	31.00	35.00	43.00	32.00	29.00	24.00	50.00	0.00	0.00	34.00
LT Debt, Current	15.5%	1.00	1.00	2.00	7.00	2.00	2.00	2.00	0.00	0.00	0.00	0.00	0.00	25.00	-	-	9.00
Shareholder's Equity	-8.6%	278	304	705	691	378	392	648	0.00	619	529	0.00	282	0.00	42.00	38.00	17.00
Retained Earnings	-9.5%	-454	-414	-374	-335	-298	-270	-175	-145	-118	-106	-114	-153	-58.78	-0.24	-0.09	-49.93
Additional Paid-In Capital	1.8%	732	719	705	691	676	662	648	633	619	636	621	436	415	5.00	5.00	67.00
Shares Outstanding	0.8%	103	102	102	102	102	101	101	101	101	100	98.00	85.00	85.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-56.5%	-15,933	-10,180	-15,286	-5,865	-4,255	-20,189	-19,788	-17,605	-15,522	-24,800	-8,433	-14,208	-3,382	-26.00	-4,774	-5,615	-
Share Based Compensation	405.2%	23,239	4,600	4,700	14,065	19,318	4,900	14,233	13,750	25,958	4,800	14,031	4,700	3,122	221	155	147	-
Cashflow From Investing	26.4%	-1,959	-2,663	-6,641	-16,400	-30,854	-42,819	-49,893	-58,916	-88,531	-196,071	-27,673	-23,893	-13,090	-6,099	-3,730	-15,340	-
Cashflow From Financing	15.3%	-458	-541	-6,510	91,539	-1,280	22,961	-7.00	78.00	194,724	289	137,755	-26,566	390,219	4,263	1,182	27,011	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	152	-	-	-

DNMR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Total revenues	$ 46,684	$ 53,218
Costs and expenses:
Cost of revenue	73,644	63,632
Selling, general and administrative	68,983	81,589
Research and development	29,242	31,939
Loss on sale of assets	246	1
Impairment of long-lived assets	188	63,491
Total costs and expenses	172,303	240,652
Loss from operations	(125,619)	(187,434)
Nonoperating income (expense):
Gain on remeasurement of private warrants	207	9,366
Interest, net	(29,641)	(1,723)
Gain on loan extinguishment	(102)	(1,500)
Other, net	1	723
Total nonoperating income (expense):	(29,535)	6,866
Loss before income taxes	(155,154)	(180,568)
Income taxes	(319)	810
Net loss	$ (155,473)	$ (179,758)
Basic net loss per share	$ (1.52)	$ (1.78)
Diluted net loss per share	$ (1.52)	$ (1.78)
Basic net loss per share	102,001,812	101,095,341
Diluted net loss per share	102,001,812	101,095,341
Products
Revenue
Total revenues	$ 44,200	$ 48,420
Services
Revenue
Total revenues	$ 2,484	$ 4,798

DNMR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 59,170	$ 62,792
Accounts receivable, net	15,227	17,989
Other receivables, net	652	1,635
Inventories, net	25,270	32,743
Prepaid expenses and other current assets	4,714	5,225
Contract assets, net	3,005	4,687
Total current assets	108,038	125,071
Property, plant and equipment, net	445,153	453,949
Intangible assets, net	77,790	80,941
Right-of-use assets	19,160	19,028
Leverage loans receivable	31,446	31,446
Restricted cash	14,334	1,609
Other assets	2,210	226
Total assets	698,131	712,270
Current liabilities
Accounts payable	5,292	14,977
Accrued liabilities	4,726	5,001
Unearned revenue and contract liabilities	1,000	0
Current portion of lease liability	3,337	3,337
Current portion of long-term debt, net	1,368	1,972
Total current liabilities	15,723	25,287
Long-term lease liability, net	21,927	22,114
Long-term debt, net	381,436	286,398
Deferred income taxes	0	200
Other long-term liabilities	1,025	659
Total liabilities	420,111	334,658
Commitments and contingencies (Note 18)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized: 102,832,103 and 101,804,454 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	10	10
Additional paid-in capital	732,131	676,250
Accumulated deficit	(454,121)	(298,648)
Total stockholders’ equity	278,020	377,612
Total liabilities and stockholders’ equity	$ 698,131	$ 712,270

About Danimer Scientific

Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles. It also markets its products to consumer packaging brand owners, converters, and manufacturers in the plastics industry. Danimer Scientific, Inc. was founded in 2004 and is headquartered in Bainbridge, Georgia.

CEO	Mr. Stephen E. Croskrey
WEBSITE	danimerscientific.com
INDUSTRY	Chemicals
EMPLOYEES	271

Danimer Scientific Frequently Asked Questions

What is the ticker symbol for Danimer Scientific? What does DNMR stand for in stocks?

DNMR is the stock ticker symbol of Danimer Scientific. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Danimer Scientific (DNMR)?

As of Mon Apr 15 2024, market cap of Danimer Scientific is 89.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNMR stock?

You can check DNMR's fair value in chart for subscribers.

What is the fair value of DNMR stock?

You can check DNMR's fair value in chart for subscribers. The fair value of Danimer Scientific is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Danimer Scientific is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Danimer Scientific a good stock to buy?

The fair value guage provides a quick view whether DNMR is over valued or under valued. Whether Danimer Scientific is cheap or expensive depends on the assumptions which impact Danimer Scientific's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNMR.

What is Danimer Scientific's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, DNMR's PE ratio (Price to Earnings) is -0.57 and Price to Sales (PS) ratio is 1.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNMR PE ratio will change depending on the future growth rate expectations of investors.